How Site Consolidation Continues to Reshape Clinical Trials
The clinical research site market is undergoing a structural shift. Over the past decade, and accelerating post-2020, independent research sites have increasingly been acquired or rolled up into multi-site networks backed by private equity and strategic investors. These networks are expanding regionally and nationally, creating larger, more centralized site organizations.
The global Site Management Organization (SMO) market was valued at approximately $6.24 billion in 2023 and is projected to reach $9.47 billion by 2030, growing at a 6.17% CAGR, driven by increased outsourcing and demand for scalable site infrastructure, according to Grand View Research.
At the same time, industry analyses continue to highlight ongoing consolidation and M&A activity across clinical trial sites into larger networks, with independent sites increasingly under shared ownership to operate as coordinated networks—a trend reinforced through insights shared at SCRS industry forums and related market analyses.
This shift is also being reinforced by changing sponsor behavior. Sponsors are increasingly consolidating site relationships, favoring fewer, higher-performing partners capable of delivering consistent results across studies and geographies. This trend reflects a broader industry push to reduce execution variability and accelerate timelines.
This is not temporary. The industry is moving from independent sites to networked research organizations.
2. Why Consolidation Is Accelerating
Sponsor Pressure is Reshaping Site Strategy
Sponsors and CROs are under increasing pressure to accelerate timelines and reduce variability across trials. According to McKinsey & Company, trial timelines remain one of the largest drivers of cost and risk in drug development, pushing sponsors to seek partners that can deliver consistency at scale.
- Clinical development timelines average ~12 years per asset
- Development costs can reach up to $2.8 billion per drug
- Up to 80% of clinical trials fail to finish on time
At the same time, trial execution is becoming more difficult:
- Enrollment productivity per site is declining
- Demand for trial participants has increased ~10% over the past decade
- Protocol complexity continues to rise, increasing operational burden on sites
As scientific advances continue, trial execution has become an increasingly important determinant of timeline, cost, and delivery.
What Sponsors Are Doing About It
In response, sponsors are fundamentally rethinking how trials are executed. They are prioritizing partners that can demonstrate:
- Faster study start-up
- Predictable enrollment performance
- Standardized execution across locations
They are also investing in real-time performance tracking, more coordinated site engagement models, and data-driven approaches to site selection and oversight.
At the same time, larger site networks are gaining advantage through:
- Shared infrastructure across locations
- Centralized staff and resources
- Greater negotiating leverage with sponsors
Private equity investment in site networks reflects this shift, reinforcing the belief that scale can drive both operational efficiency and performance consistency.
🎯 Outcome: Sponsors are no longer expanding their site footprint indiscriminately. They are consolidating relationships toward fewer, higher-performing networks that can deliver consistent, repeatable execution at scale.
3. The Illusion of Scale vs. Actual Scale
Most networks mistake growth for scale. But growth in site count is not the same as operational scale. Many networks expand by acquiring or affiliating sites, but fail to unify how those sites operate. The result:
- Study start-up timelines vary significantly by location
- Performance data is fragmented across systems
- Reporting requires manual aggregation
- Leadership lacks real-time visibility into execution
This creates what can be described as “organizational scale without operational coherence.” In practice, these networks are not operating as one system. They are operating as a collection of sites.
4. The Emerging Divide: Aggregated vs. Integrated Networks
As consolidation continues, a clear divide is emerging between two models:
Aggregated Networks
- Grow through acquisition or affiliation
- Operate site by site with local processes and tools
- Data remains fragmented across systems
- Performance must be manually reconstructed
Integrated Networks
- Built on centralized operational infrastructure
- Standardize workflows across all locations
- Unify study start-up and feasibility processes
- Operate with real-time visibility across the portfolio
This distinction is increasingly important. Site performance variability remains a major contributor to delays in clinical trials, reinforcing the need for greater standardization and coordination across sites.
🎯 Implication: The competitive advantage is shifting: From network size to network execution capability.
5. What the Shift Requires - The Operating Model Must Change
Beyond growth, the core issue is how growth is managed. Traditional site operating models built around site-level autonomy, disconnected systems (CTMS, eReg, spreadsheets, email), and retrospective reporting were never designed to support multi-site scale.
- As networks grow, these models introduce:
- Visibility gaps
- Operational variability
- Delayed decision-making
- Increased execution risk
What’s emerging instead is the need for an integrated and centralized research operating model:
- A system that governs workflows across all sites
- A unified layer for study start-up, execution, and oversight
- Real-time operational intelligence, not reconstructed reporting
Because at scale, running trials is no longer a site-level activity. It is a network-level operation. But what does that actually look like in practice?
6. What Leading Networks Are Implementing
Solutions like RealTime-Devana are emerging to address a specific gap in multi-site research: the ability to manage clinical trial operations at the network level, not just the site level.
Devana sits at the center of trial operations — where pipeline, study start-up, and performance oversight converge — providing a single system to coordinate activity across all locations.
But what’s more important than the solution itself is the model it represents.
A Site Operations Management System - From Tools to an Operating Layer
As networks scale, the limitation isn’t the systems themselves; it’s that they operate independently. CTMS, manual document management, paper source documentation, email threads, and spreadsheets for reporting each solve part of the problem. None are designed to govern execution across a network.
This is where a new approach is emerging: A Site Operations Management System (SOMS), a centralized operating layer for clinical research sites that:
- governs workflows across sites
- standardizes study start-up and execution
- captures operational data as work happens
- provides real-time visibility across the portfolio
In this model, systems are no longer just connected. They operate as a single system of execution.
What This Looks Like in Practice
Within a SOMS model approach, clinical research site networks and multi-site organizations can:
- manage pipeline and feasibility across all sites in one system
- standardize and track study start-up timelines across locations
- monitor enrollment and study performance in real time
- forecast capacity and revenue across the network
- provide leadership with portfolio-level visibility without manual aggregation
This is a shift from tracking work to governing execution. Networks that adopt this model move beyond:
- managing individual sites to operating as a coordinated network
- fragmented reporting to real-time operational intelligence
- reactive execution to predictable performance at scale
The advantage is no longer defined by how many sites a network owns. It’s defined by how effectively those sites operate as one system.
Playbook Takeaway
- Consolidation is accelerating and raising the bar for site performance
- Growth without operational alignment creates risk, not scale
- A divide is emerging between aggregated and integrated networks
- The next competitive advantage will be defined by how networks operate as one system